Benzinga · Oct 26, 2026
This Tesla Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday
Analysts upgraded SAFE, CNOB, LMT and more.
TT
NASDAQ · TTRX
Turn Therapeutics Inc.
Healthcare · Biotechnology
$10.43
Down-$0.29 (-2.71%)
Updated Nov 2, 2026, 12:56 PM
SID Score
5.2/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 96.14M
- P/E ratio
- 0
- Dividend yield
- 0.00%
- 52-week range
- $2.57 – $16.45
- Volume
- 137.08K
- Avg. volume
- 595.4K
Price performance · TTRX
TTRX price history
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 30, 2026
TTRX closed at $10.43 after 20 trading sessions, down 15.61% for the selected period.
- Last close
- $10.43
- Period change
- -15.61%
- Period low
- $10.15
- Period high
- $12.36
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 30, 2026 | $10.45 | $10.585 | $9.60 | $10.43 | 137.08K |
| Oct 29, 2026 | $10.91 | $11.31 | $10.65 | $10.72 | 137.71K |
| Oct 28, 2026 | $10.48 | $11.55 | $10.2804 | $11.12 | 70.39K |
| Oct 27, 2026 | $10.55 | $10.83 | $10.1015 | $10.42 | 98.42K |
| Oct 26, 2026 | $10.16 | $10.82 | $10.04 | $10.61 | 98.18K |
| Oct 23, 2026 | $10.59 | $10.79 | $10.091 | $10.28 | 87.05K |
| Oct 22, 2026 | $10.05 | $10.47 | $9.83 | $10.18 | 113.12K |
| Oct 21, 2026 | $10.61 | $10.715 | $10.14 | $10.15 | 60.58K |
| Oct 20, 2026 | $10.54 | $10.74 | $10.28 | $10.47 | 76.91K |
| Oct 19, 2026 | $10.72 | $10.87 | $10.60 | $10.74 | 29.91K |
| Oct 16, 2026 | $11.49 | $11.49 | $10.39 | $10.57 | 105.63K |
| Oct 15, 2026 | $10.85 | $11.885 | $10.85 | $11.59 | 80.34K |
| Oct 14, 2026 | $10.42 | $11.44 | $10.42 | $11.11 | 53.37K |
| Oct 13, 2026 | $11.12 | $11.398 | $10.26 | $10.60 | 117.45K |
| Oct 12, 2026 | $11.72 | $11.985 | $11.03 | $11.11 | 45.98K |
| Oct 9, 2026 | $11.34 | $12.00 | $11.30 | $12.00 | 109.83K |
| Oct 8, 2026 | $11.94 | $12.00 | $11.24 | $11.39 | 110.13K |
| Oct 7, 2026 | $11.58 | $13.05 | $11.31 | $12.10 | 176.32K |
| Oct 6, 2026 | $12.35 | $12.42 | $11.57 | $11.64 | 74.85K |
| Oct 5, 2026 | $13.18 | $13.18 | $12.00 | $12.36 | 111.34K |
Latest TTRX news
The latest Smart Investors Daily articles mentioning TTRX.
Stock researchCompany · Overview
Company
Market Activity
Research & News
TTRX research
Overview
Company profile and research snapshot.
Company profile
Turn Therapeutics Inc is a clinical-stage biotechnology company focused on developing pharmaceutical and medical device products for dermatology, wound care, and infectious disease. The company's proprietary platform technology, called PermaFusion, enhances drug performance by improving the stability and bioavailability of active pharmaceutical ingredients, which allows for reduced doses and fewer side effects. Its primary development programs target skin conditions such as moderate to severe eczema and onychomycosis.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 23, 2026 | WBB Securities | Hold | — |
| Sep 24, 2026 | LUCID CAPITAL MARKETS | Buy | — |
| Sep 14, 2026 | WBB Securities | Sell | — |
| Mar 24, 2026 | D. Boral Capital | Buy | — |
| Jan 20, 2026 | D. Boral Capital | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Oct 23, 2026
This Allegion Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Raymond James
Benzinga · Oct 23, 2026
WBB Securities Upgrades Turn Therapeutics to Hold, Maintains Price Target to $10
WBB Securities analyst Karen Sterling upgrades Turn Therapeutics (NASDAQ:TTRX) from Sell to Hold and maintains the price target from $10 to $10.
Yahoo · Oct 21, 2026
U.S. Bancorp | BTIG to Host Turn Therapeutics for Virtual Fireside Chat
WESTLAKE VILLAGE, Calif., October 21, 2026--Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted, non-systemic therapies for inflammatory skin diseases, today announced that Bradley Burnam, Chief Executive Officer, and Stephen M. Hahn, M.D., Executive Clinical and Regulatory Lead, will join in a U.S. Bancorp | BTIG virtual fireside chat as follows:
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
